KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Sales: 2020-2025

Historic Return on Sales for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to -16.38%.

  • Recursion Pharmaceuticals' Return on Sales fell 1058.00% to -16.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.38%, marking a year-over-year decrease of 1058.00%. This contributed to the annual value of -7.88% for FY2024, which is 52.00% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Return on Sales stood at -16.38%, which was down 62.98% from -10.05% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Return on Sales' 5-year high stood at -5.31% during Q2 2023, with a 5-year trough of -17.96% in Q4 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Return on Sales averaged around -8.12%, with its median value being -7.55% (2024).
  • Its Return on Sales has fluctuated over the past 5 years, first spiked by 1,179bps in 2022, then tumbled by 1,058bps in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Return on Sales stood at -17.96% in 2021, then soared by 1,179bps to -6.17% in 2022, then crashed by 119bps to -7.36% in 2023, then crashed by 52bps to -7.88% in 2024, then crashed by 1,058bps to -16.38% in 2025.
  • Its Return on Sales was -16.38% in Q3 2025, compared to -10.05% in Q2 2025 and -9.61% in Q1 2025.